[Preliminary phase II study of cis-Dichlorodiammineplatinum (II) in patients with non-small cell carcinoma of the lung and metastatic pulmonary tumor].
A preliminary phase II study of cis-Dichlorodiammineplatinum (II) was carried out in 17 patients with non-small cell carcinoma (12 adenocarcinomas, 3 squamous cell carcinomas, 2 large cell carcinoma) of the lung, and in 15 patients with metastatic pulmonary tumor. All patients could be evaluated. A partial response was obtained in 2 of 12 adenocarcinoma patients and in 1 of 3 patients with squamous cell carcinoma, resulting in a partial response rate of 17.6%. A partial response was also obtained in one patient each from those with metastatic pulmonary tumor from the uterus, skin and pharynx and in patients with mediastinal tumor, resulting in a partial response rate of 26.7%. There was mild myelosuppression in our patients; renal toxicity and toxic neuropathy seemed to be the dose-limiting factors in cis-Dichlorodiammineplatinum (II) therapy.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged
D002945:Cisplatin